PUB - Publikationen an der Universität Bielefeld

INTRODUCTION: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes.; PATIENTS AND METHODS: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0months compared standard salvage chemotherapy (FLAG-Ida or HAM in n=35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n=18 patients) concerning safety and efficacy.; RESULTS: Regarding the primary endpoints, there was a statistically significant increased eventfree survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy based on the univariate log-rank-test and in the multivariate Cox regression analysis (HR 0.22 [95% CI 0.05, 0.97]). There were no differences between the two groups in terms of patients developing febrile neutropenia CTCAE III° and IV° or a delay in hematological recovery. In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group.; CONCLUSIONS: The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy. © 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.